Prolonged exposure, or PE, is a trauma-focused cognitive behavioral therapy recommended by the American Psychological Association, the International Society for Traumatic Stress Studies, and the joint clinical practice guidelines of the U.S. Departments of Veterans Affairs and Defense. Over the course of roughly eight to fifteen sessions, patients repeatedly revisit the memory of their single most distressing traumatic experience—known as the index event—during imaginal exposure conducted in session, while also completing behavioral homework in which they gradually approach objectively safe reminders of the trauma in daily life. The treatment works, but emotional activation is built into its design. Under emotional processing theory, the framework that underpins PE, activating the fear structure in memory is considered necessary for corrective learning to occur. The catch is that this same emotional intensity is a leading explanation for the treatment’s elevated dropout rates. In one study cited by the research team, 60 percent of participants who dropped out said it was because the treatment was too stressful.

The new analysis, led by Kiara H. Buccellato of The University of Texas at San Antonio and colleagues with the Consortium to Alleviate PTSD, compared two ways of delivering the imaginal exposure component of PE. In the standard approach, participants focused solely on their single most distressing traumatic event from the outset—a strategy that, in the terminology of anxiety treatment, resembles flooding. In the modified, graduated approach, participants instead identified their top three most distressing events and began imaginal exposure with the third most distressing, repeating that exercise in every session until it no longer provoked strong distress before moving on to the second most distressing event, and finally the worst. This hierarchical strategy has long been standard practice in the treatment of anxiety disorders generally, and in the in vivo, between-session homework portion of PE itself, but it had never been rigorously applied to the imaginal exposure core of PTSD treatment.

The data came from a larger randomized clinical trial conducted between 2017 and 2019 at four sites in Texas, in which 234 active duty service members and veterans with PTSD were assigned to one of two intensive PE protocols. Both involved fifteen 90-minute sessions delivered over just three weeks. One group received massed PE, the standard protocol, while the other received an intensive outpatient version that added eight treatment enhancements—the most consequential being the identification of the top three traumas and graduated imaginal exposure, along with team-based treatment, clinic-based completion of homework, twice-daily therapist feedback sessions, enhanced social support involving a spouse or close friend, a brief timeline review of all lifetime traumas, and posttreatment booster sessions at one, three, and seven weeks. The present secondary analysis drew on 199 participants from three sites where distress ratings had been systematically recorded: 96 in the standard exposure group and 89 in the graduated group, covering 267 unique traumatic events.

Distress was measured with the Subjective Units of Distress Scale, or SUDS, a well-established clinical instrument in which 0 represents a state of absolute calmness and 100 represents the worst anxiety ever experienced. The researchers defined peak SUDS as the highest distress rating a participant endorsed for each traumatic memory across all treatment sessions, and compared average peak values between groups using analysis of variance with planned contrasts and Cohen’s d effect sizes.

The results were striking. Participants receiving standard exposure, confronting their worst memory from the start, reported an average peak SUDS of 88.06—just shy of the top of the scale. Participants in the graduated group reported an average peak of 75.19 for their most distressing event, a difference that was highly statistically significant with a medium-to-large effect size of 0.70. The graduated group also showed significantly lower peak distress for their second most distressing event (72.23, compared to the standard group’s 88.06, d = 0.81) and their third most distressing event (74.63, d = 0.69). Taken together, participants using graduated exposure experienced significantly lower average peak distress across all events combined—74.02 versus 88.06, d = 0.72. The overall effect of treatment group on peak distress was significant, F(3,359) = 12.46, p < .001.

The sample was largely male (79.9 percent) with a mean age of 38.5 years, and ethnically diverse: 41.2 percent identified as non-Hispanic White, 28.6 percent as African American, 25.6 percent as Hispanic, and 4.5 percent as other. The two groups were statistically indistinguishable on age, gender, rank, race and ethnicity, education, military status, and service history, with marital status the only demographic variable that differed.

Why does the ordering of traumatic memories matter so much? The researchers point to the psychology of treatment attrition. A national qualitative study of veterans cited in the paper found that treatment completers and dropouts interpreted their distress in fundamentally different ways: completers read intense distress as evidence that treatment was working, while dropouts read it as a sign their symptoms were worsening and the therapy was failing them. Crucially, 70 percent of those who dropped out did so between sessions three and six—precisely the window when early imaginal exposure sessions occur. By easing patients in with a less catastrophic memory, the graduated approach may allow them to build confidence and mastery before facing their worst experience, reducing the anticipatory anxiety that keeps many veterans from starting trauma-focused therapy at all.

The military context makes the graduated approach especially compelling. PE was originally developed with women sexual assault survivors, for whom a single clearly identifiable index trauma was often available. Combat environments are different: service members frequently accumulate multiple traumatic exposures—combat, childhood adversity, military sexual trauma—spanning several categories, making the selection of one “worst” event both difficult and arguably incomplete. Addressing the top three events allows treatment to encompass a broader range of experiences, and different trauma types map onto different PTSD symptom clusters, with combat trauma linked more strongly to intrusion and arousal symptoms and sexual trauma to avoidance and cognitive-mood symptoms. A single-event focus may leave this cumulative burden partially unaddressed.

The modified protocol has already shown clinical promise. The primary outcomes of the parent trial, published in JAMA Network Open, demonstrated significant reductions in clinician-rated and self-reported PTSD severity in both groups, with PTSD diagnostic remission rates of 48 percent for the intensive outpatient group and 61 percent for the massed group at posttreatment, and roughly 50 percent for both at six-month follow-up. Earlier work by McLay and colleagues on virtual reality graduated exposure therapy had also found greater symptom improvement in a graduated group compared to treatment-as-usual, though that study’s broad control group limited the comparison.

The authors are careful about the study’s limits. The graduated and standard groups differed in more than one way—the graduated approach was only two of eight enhancements distinguishing the intensive outpatient protocol—so other components, such as enhanced social support, could contribute to the distress differences observed. Because distress reduction was not manipulated in isolation, the specific causal effect of graduated versus traditional imaginal exposure on outcomes and dropout cannot be isolated from these data. There is also a theoretical tension to resolve: emotional processing theory holds that some degree of distress is essential for therapeutic gain, and the researchers note that some patients who interpret low distress as a sign that treatment is not working might paradoxically disengage. Future research, they argue, should hold the treatment modality constant except for the exposure ordering, and track both distress over time and attrition directly.

Even with those caveats, the findings carry real weight for clinical practice. A therapy that asks people to walk back into their worst moments will always demand courage; the question is whether the door has to open all at once. This study, the first to directly compare patient-reported distress during graduated versus traditional imaginal exposure for PTSD, suggests it does not. Average peak distress fell by roughly 13 to 16 points on a 100-point scale—a margin that could mean the difference between a veteran who walks out of session three and one who walks back in for session four. As the authors conclude, making evidence-based trauma therapy more tolerable may be one of the most practical ways to ensure that the people who need it most actually stay long enough to be helped by it.

The need for new approaches is substantial. Approximately 17.5 veterans die by suicide every day in the United States, according to data cited by the U.S. Department of Veterans Affairs, while about 7 percent of veterans are diagnosed with PTSD each year. The disorder can emerge after exposure to combat, sexual or physical violence, serious accidents, natural disasters or other traumatic events that overwhelm a person’s ability to cope. Although PTSD is often associated with military service, it affects civilians as well, and lifetime prevalence in the general population is estimated at approximately 6 percent. Women and veterans experience the condition at higher rates than many other groups. Symptoms can include intrusive memories, nightmares, emotional numbness, hypervigilance, avoidance and persistent changes in mood or cognition.

Since PTSD became an official psychiatric diagnosis in 1980, the main treatment options have remained psychotherapy and medications, particularly selective serotonin reuptake inhibitors such as sertraline and fluoxetine. These interventions can be effective, but they do not work for everyone. A 2020 review of pharmacological treatments found that average improvements were modest, with patient-reported symptom reductions ranging from 6.8 to 10.1 points and remission rates reaching no more than 10.9 percent in the studies analyzed. Psychotherapy can also be highly beneficial, but trauma-focused treatments require sustained participation and may temporarily intensify anxiety. Some patients discontinue treatment because confronting traumatic memories is too distressing. The limited response to existing options has created an urgent demand for therapies that are both effective and better matched to individual biology.

MeRT attempts to address that problem by measuring the electrical behavior of the brain before treatment begins. During an electroencephalogram, or EEG, sensors positioned on the scalp detect fluctuations in electrical activity produced by networks of neurons. The resulting signal is not a direct image of individual neurons, but it provides information about the timing, frequency and coordination of activity across the brain. PTSD has been associated with disruptions in several aspects of neural regulation, including arousal, emotional processing and communication between brain regions. MeRT uses EEG data to generate a patient-specific profile, which is then analyzed by an algorithm designed to identify patterns that may be relevant to treatment. Instead of applying an identical stimulation protocol to every patient, clinicians use the profile to guide the frequency, timing and location of magnetic stimulation.

The treatment itself relies on transcranial magnetic stimulation, or TMS, a noninvasive technique that uses a coil placed against the scalp to generate rapidly changing magnetic fields. These fields pass through the skull and induce small electrical currents in targeted areas of the brain. TMS has already been cleared by the FDA for conditions including treatment-resistant depression, and it is also used in other neurological and psychiatric applications. In conventional TMS, treatment parameters are often selected according to standardized clinical protocols. MeRT adds EEG-based analysis and what Wave Neuroscience describes as an augmented, artificial-intelligence-derived multivariate algorithm. The purpose is not to replace clinical judgment, but to use measurable physiological information to refine stimulation for the individual receiving care.

According to Erik Won, Wave Neuroscience’s chief medical officer, the company’s FDA trial produced a 52 percent reduction in PTSD symptoms and a remission rate of 68 percent. Won characterized those findings as a more than fourfold increase in symptom improvement compared with the results of the 2020 medication review. The treatment course in the trial consisted of five sessions per week over five to six weeks, and researchers reported that beneficial effects appeared to persist after treatment ended. The findings have not yet been fully processed for public dissemination, and the reported outcomes should therefore be interpreted as preliminary until detailed trial data, including the study design, control conditions, sample size, statistical analysis and follow-up results, are available for independent evaluation. Nevertheless, the figures have generated intense interest because they suggest the possibility of a substantial response in a population that often struggles with incomplete recovery.

Texas A&M researchers played several roles in the project. Kenneth S. Ramos, a physician-scientist at the Texas A&M Health Institute of Biosciences and Technology, contributed expertise in precision medicine, a field that seeks to tailor prevention and treatment to the biological characteristics of individual patients. Ramos has compared conventional TMS to placing a tarp over a leaking roof: useful for addressing the immediate problem, but not necessarily targeted at the underlying source. In his analogy, MeRT is more like identifying the damaged shingles and replacing them directly. The comparison reflects the central premise of the technology—that differences in brain physiology may help determine which treatment parameters are most likely to produce a meaningful response. Even small biological variations between people can influence how psychiatric disorders develop and how patients respond to intervention.

Rick Silva, executive director of clinical trials at the Texas A&M institute, said the project moved from its beginnings during the COVID-19 pandemic to FDA clearance in slightly more than two years, a notably rapid timeline compared with the decade often required for medical devices to complete development, testing and regulatory review. MeRT received FDA breakthrough device designation in 2024, a program intended to accelerate the review of technologies that may provide more effective treatment for life-threatening or irreversibly debilitating conditions. Breakthrough designation does not eliminate the need for scientific evidence or safety evaluation, but it can facilitate communication between developers and regulators and help streamline aspects of the review process. The eventual clearance represents a significant regulatory milestone, although clearance is not the same as proof that a treatment will work for every patient or eliminate the need for clinical oversight.

Israel Liberzon, a distinguished professor of psychiatry and behavioral sciences at the Texas A&M Naresh K. Vashisht College of Medicine, served as the study’s lead psychiatrist and PTSD expert. He described the technology as an important addition to the treatment landscape because it provides a non-medication option alongside psychotherapy and existing drugs. At present, the FDA has approved two medications specifically for PTSD, both SSRIs, while psychotherapy remains a central component of clinical care. MeRT could be particularly relevant for patients who experience medication side effects, fail to respond to antidepressants or cannot complete trauma-focused therapy. However, the treatment still requires repeated visits, specialized equipment and trained clinicians. Access, insurance coverage and cost will determine whether the technology reaches the millions of people who might benefit from it rather than remaining concentrated in a limited number of treatment centers.

Wave Neuroscience has presented the clearance as part of a broader effort to make mental healthcare more objective and data-informed. Leslie S. Prichep, the company’s chief scientific officer, said the system builds on decades of research into electrophysiological biomarkers—measurable features of brain activity that may help characterize abnormal neural states and guide intervention. The company is also exploring potential applications in depression, anxiety and other conditions. Yet the scientific challenge remains significant: psychiatric disorders are biologically complex, symptoms can arise through multiple pathways, and EEG patterns may vary with sleep, medication, stress and other factors. Continued independent studies will be needed to determine how reliably the system identifies treatment targets, whether the reported benefits exceed placebo and nonspecific effects, how long improvements last, and which patients are most likely to respond.

For veterans and civilians living with PTSD, the arrival of a personalized neuromodulation system offers a reason for cautious optimism. A treatment that can measure brain activity, adjust stimulation and potentially reduce symptoms without medication could reshape expectations for people who have exhausted conventional options. At the same time, researchers emphasize that no single therapy should be regarded as a universal cure. PTSD remains a heterogeneous disorder requiring comprehensive assessment, informed consent and individualized clinical care. The collaboration between Texas A&M Health and Wave Neuroscience illustrates how precision medicine is moving from genetics and cancer treatment into psychiatry, where the brain’s electrical signals may provide a new route to personalization. If future trials confirm the early results, MeRT could become one of the most closely watched developments in PTSD care—and a highly visible test of whether brain-based precision medicine can deliver on its promise.

Subject of Research: Personalized Magnetic e-Resonance Therapy (MeRT) using EEG-guided transcranial magnetic stimulation for post-traumatic stress disorder.

Article Title: New EEG-Guided Brain Stimulation System Offers a Personalized Path for PTSD Treatment

News Publication Date: Not provided in the source material.

Web References: https://www.waveneuro.com/mert ; https://www.accessdata.fda.gov/cdrh_docs/pdf26/K260402.pdf ; https://ibt.tamu.edu/ ; https://medicine.tamu.edu/faculty-listings/ramos.html

References: U.S. Department of Veterans Affairs PTSD and veteran suicide data; National Institute of Mental Health PTSD statistics; 2020 review of PTSD medications, https://pubmed.ncbi.nlm.nih.gov/33049805/ ; FDA Breakthrough Devices Program, https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program

Keywords: PTSD, post-traumatic stress disorder, veterans, suicide prevention, precision medicine, Magnetic e-Resonance Therapy, MeRT, transcranial magnetic stimulation, TMS, EEG, brain mapping, artificial intelligence, personalized psychiatry, Texas A&M Health, Wave Neuroscience